Poster Presentation Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Report on a Consecutive Series of Ipilimumab Treated Metastatic Melanoma Patients at a Single Australian Institution (#217)

Rachael Chang 1 , Michael Brown 1 , Feruza Kholmurodova 2
  1. Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia
  2. Flinders University, Adelaide, SA, Australia


Immune checkpoint inhibitors have become the standard treatments for metastatic melanoma. Serious immune-related adverse events are common. We reviewed our experience with ipilimumab to document overall survival rate at 2 years, factors associated with improved outcomes and immune related adverse events (irAEs).


We conducted retrospective analysis of 43 patients treated with ipilimumab for metastatic melanoma at Royal Adelaide Hospital between July 2010 and December 2013. Data was collected on patient demographics, treatment history, BRAF mutation status, baseline LDH, change in lymphocyte counts, brain metastases and grade 3/4 irAEs. A Kaplan Meier survival analysis was performed.


The estimated median OS was 9 months and the 2 year survival rate was 14%. At a median follow up of 66 months, a plateau in survival curve seemed evident at 3 years. Median PFS was 5 months and median TTF was 4 months.

Age (P<0.001, HR 0.94, 95% CI 0.9-0.97), increase in lymphocyte count from baseline to after 2 cycles of ipilimumab (P<0.009, HR 0.40, 95% CI 0.2-0.8), absence of brain metastases (P<0.002, HR 0.1, 95% CI 0.02-0.42) and subsequent treatment after ipilimumab (P<0.00, HR 0.08, 95% CI 0.02-0.3) were associated with improved survival. Baseline LDH, prior treatment, blood eosinophilia and BRAF mutation status did not affect overall survival.

Activity of ipilimumab in patients with brain metastases was also noted with median survival of 23 months.

Out of 15 patients (35%) who experienced grade 3/4 irAEs, GI toxicity was most common. One patient with retinopathy, one with Guillain Barre Syndrome, two with colitis and hypophysitis are still alive, indicating possible relationship between grade 3/4 irAEs and survivability.


At a single Australian institution, ipilimumab has shown efficacy and tolerability similar to those seen in pivotal clinical trials. Grade 3 and 4 toxicities were common and prognostic markers may indicate those most likely to benefit.


  1. Dirk Schadendorf, F. Stephen Hodi, et all:Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma : CO Jun 10, 2015:1889-1894; DOI:10.1200/JCO.2014.56.2736.
  2. Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang,et all: Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center : JCO Oct 1, 2015:3193-3198; DOI:10.1200/JCO.2015.60.8448.
  3. Michele Maio, Jean-Jacques Grob, et all: Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial : JCO Apr 1, 2015:1191-1196; DOI:10.1200/JCO.2014.56.6018.
  4. F. Stephen Hodi, M.D., Steven J. O'Day, M.D., David F. McDermott, et all :Improved Survival with Ipilimumab in Patients with Metastatic Melanoma: N Engl J Med 2010; 363:711-723August 19, 2010DOI: 10.1056/NEJMoa1003466
  5. Marliese Alexander, James D Mellor, Grant McArthur and Damien Kee: Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma: Med J Aust 2014; 201 (1): 49-53. doi:10.5694/mja13.10448
  6. Christian U. Blank and Alexander Enk:Therapeutic use of anti-CTLA-4 antibodies:International Immunology ,doi:10.1093/intimm/dxu076